A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- Acronyms MS-BMD
- 15 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 15 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2013 New trial record